Advertisement

Serotonin in migraine: Theories, animal models and emerging therapies

  • Kirk W. Johnson
  • Lee A. Phebus
  • Marlene L. Cohen
Part of the Progress in Drug Research book series (PDR, volume 51)

Summary

A role for serotonin in migraine has been supported by changes in circulating levels of serotonin and its metabolites during the phases of a migraine attack, along with the ability of serotonin-releasing agents to induce migraine-like symptoms. The development of serotonin receptor agonists with efficacy in the clinic for the alleviation of migraine pain further implicates serotonin as a key molecule in migraine.

Several theories regarding the etiology of migraine have been proposed. The vasodilatory theory of migraine suggested that extracranial arterial dilation during an attack was related to migraine pain; a theory supported when vasoconstrictors such as sumatriptan alleviated migraine pain. The neurological theory of migraine proposed that migraine resulted from abnormal firing in brain neurons. Cortical spreading depression, one facet of the neurological theory, could explain the prodrome of migraine. The neurogenic dural inflammation theory of migraine supposed that the dural membrane surrounding the brain became inflamed and hypersensitive due to release of neuropeptides from primary sensory nerve terminals. Substance P, calcitonin gene related peptide and nitric oxide are all though to play a role in the dural inflammatory cascade.

Animal models of migraine have been utilized to study the physiology of migraine and develop new pharmaceutical therapies. One model measures the shunting of blood to arterovenous anastomoses based on a proposal that migraine primarily involves cranial arteriovenous vasodilation. Another model utilizes electrical stimulation of the trigeminal ganglion to indoce neurogenic dural inflammation quantified by the resulting extravasation of proteins. Pharmacological agents such as meta-chlorophenylpiperazine (mCPP) and nitroglycerin have also been used to induce dural extravasation in animals. Both compounds also induce migraine attacks in individuals with a history of migraine. In addition, Fos, a protein produced by activation of the c-fos gene, has been measured as an index of migraine-like pain transmission to the CNS following chemical or electrical stimulation of the trigeminal nerve.

A role for serotonin in migraine is further supported by the efficacy of serotonin receptor ligands. Sumatriptan is an agonist at 5-HT1D and 5-HT1B receptor subtypes, and effective in treating migraine pain and associated symptoms. Recently, selective 5-HT1F agonists have been proposed for the treatment of migraine, without the side effects associated with the present 5-HT1D and 5-HT1B receptor agonists. A role for 5-HT2B receptors has also been suggested in the initiation of migraine, supporting use of selective 5-HT2B receptor antagonists in migraine. Thus, agents that modulate 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2B receptors either have or may have clinical utility in the therapy of migraine headache.

Keywords

review serotonin migraine animal models neurogenic inflammation dural protein extravasation 5-HT1B receptor, 5-HT1D receptor, 5-HT1F receptor, 5-HT2B receptor nitric oxide clinical therapies serotonin agonists serotonin antagonists substance P calcitonin gene-related peptide 

Glossary of abbreviations

5-HIAA

5-hydroxyindole acetic acid

5-HT

5-hydroxytryptamine (serotonin)

CGRP

calcitonin gene-related peptide

mCPP

meta-chlorophenylpiperazine

NO

nitric oxide

CNS

central nervous system

L-NAME

N-nitro-L-arginine methyl ester

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sicuteri F., Testi A. and Anselmi B.: Int. Arch. Allergy 19, 55–58 (1961).Google Scholar
  2. 2.
    Curran D.A., Hinterberger H. and Lance J.W.: Brain 88, 997–1007 (1965).PubMedGoogle Scholar
  3. 3.
    Anthony M., Hinterberger H.J. and Lance J.W.: Arch. Neurol. 16, 544–552 (1967).PubMedGoogle Scholar
  4. 4.
    Ferrari M.D., Odink J., Tapparelli C., Van Kempen G.M.J., Pennings E.S.M. and Bruyn G.W.: Neurology 39, 1239–1242 (1989).PubMedGoogle Scholar
  5. 5.
    Fozard J.R.: Prog. Pharmacol. 4, 135–146 (1982).Google Scholar
  6. 6.
    Griffith S.C. and Burnstock G.: Lancet 1, 561–562 (1983).PubMedGoogle Scholar
  7. 7.
    Carroll J.D. and Hilton B.T.: Headache 14, 149–156 (1974).PubMedGoogle Scholar
  8. 8.
    Del Bene E., Anselmi B., Del Bianco P.L., Fanciullacci M., Gali P., Salmon S. and Sicuterri F., in: E Sicuteri (ed.): Headache, new vistas. Biomedical Press, Florence 1977, pp. 101–109.Google Scholar
  9. 9.
    Graham J.R. and Wolff H.G.: Arch. Neurol. Psychia. 39, 737–763 (1938).Google Scholar
  10. 10.
    Nichols E.T., Mawad M. and Mohr J.P.: Stroke 21, 555–559 (1990).PubMedGoogle Scholar
  11. 11.
    Dahl A., Russell D., Nyberg-Hansen R. and Rootwelk K.: Cephalalgia 10, 87–94 (1990).PubMedGoogle Scholar
  12. 12.
    Kimball R., Friedman A. and Vallejo E.: Neurology 10, 107–111 (1960).PubMedGoogle Scholar
  13. 13.
    Saxena P.R., in: J.N. Blau (ed.): Migraine — therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 581–596.Google Scholar
  14. 14.
    Saxena P.R., in: J. Olesen and M.A. Moskowitz (eds.): Experimental headache models in animal and man. Lippincott-Raven Publishers, Philadelphia 1995, 189–198.Google Scholar
  15. 15.
    Andersen A.R., Freiberg L., Olsen T.S. and Olesen J.: Arch. Neurol. 45, 154–159 (1988).PubMedGoogle Scholar
  16. 16.
    Ferrari M.D., Haan J., Blokland J.A.K., Arndt J.W., Minnee P., Zwinderman A.H., Pauwels E.K.J. and Saxena P.R.: Arch. Neurol. 52, 135–139 (1995).PubMedGoogle Scholar
  17. 17.
    Zwetsloot C.P., Caekebeke J.F.V. and Jansen J.C.: Cephalalgia 11, 103–107 (1991).PubMedGoogle Scholar
  18. 18.
    Zwetsloot C.P., Caebeke J.F.V. and Ferrari M.D.: Stroke 24, 1335–1338 (1993).PubMedGoogle Scholar
  19. 19.
    Olsen J. and Paulson O.B.: Stroke 2, 148–159 (1971).Google Scholar
  20. 20.
    Wei E.P., Moskowitz M.A., Boccalini P. and Kontos H.A.: Circ. Res. 70, 1313–1319 (1992).PubMedGoogle Scholar
  21. 21.
    Goadsby P.J. and Edvinsson L.: Ann. Neurol. 33, 48–56 (1993).PubMedGoogle Scholar
  22. 22.
    Moskowitz M.A.: Trends Pharmacol. Sci. 13, 307–311 (1992).PubMedGoogle Scholar
  23. 23.
    Pearce J.M.S.: Lancet 2, 86–89 (1984).PubMedGoogle Scholar
  24. 24.
    Moskowitz M.A., Nozaki K. and Kraig R.P.: J. Neurosci. 13, 1167–1177 (1993).PubMedGoogle Scholar
  25. 25.
    Moskowitz M.A.: Neurology 43, S 16–20 (1993).Google Scholar
  26. 26.
    Markowitz S., Saito K. and Moskowitz M.A.: J. Neurosci. 7, 4129–4136 (1987).PubMedGoogle Scholar
  27. 27.
    Moskowitz M.A.: Neurology 41, 182–186 (1991).PubMedGoogle Scholar
  28. 28.
    Ray B.S. and Wolff H.G.: Arch. Surg. 41, 813–856 (1940).Google Scholar
  29. 29.
    Goadsby P.J., Zagami A.S. and Lambert G.A.: Headache 31, 365–371 (1991).PubMedGoogle Scholar
  30. 30.
    Goadsby P.J., Edvinsson L. and Ekman R.: Ann. Neurol. 23, 193–196 (1988).PubMedGoogle Scholar
  31. 31.
    Moskowitz M.A., Lee W.S. and Cutrer E.M., in: P. Geppetti and P. Holzer (eds.): Neurogenic Inflammation, CRC Press, New York 1996, 187–199.Google Scholar
  32. 32.
    Beattie D.T., McNeil D.K. and Connor H.E.: Neuropeptides 213, 228–230 (1993).Google Scholar
  33. 33.
    Dimitriadou V., Buzzi M.G., Moskowitz M.A. and Theoharides T.C.: Neuroscience 44, 97–112 (1991).PubMedGoogle Scholar
  34. 34.
    Dimitriadou V., Buzzi M.G., Theoharides T.C. and Moskowitz M.A.: Neuroscience 48, 187–203 (1992).PubMedGoogle Scholar
  35. 35.
    Brain S.D. and Williams T.J.: Br. J. Pharmacol. 86, 855–860 (1985).PubMedGoogle Scholar
  36. 36.
    Le Greves P., Nyberg F., Terenius L. and Hokfelt T.: Eur. J. Pharmacol. 115, 309–311 (1985).PubMedGoogle Scholar
  37. 37.
    Olesen J., Thomsen L.L. and Iversen H.K.: Trends Pharmacol. Sci. 15, 149–153 (1994).PubMedGoogle Scholar
  38. 38.
    Olesen J., Inversen H.K. and Thomsen L.L.: Neuroreport 4, 1027–1030 (1993).PubMedGoogle Scholar
  39. 39.
    Thomsen L.L., Kruuse C., Iversen H.K. and Olesen J.: Eur. J. Neurol. 1, 73–80 (1994).Google Scholar
  40. 40.
    Lassen L.H., Ashina M., Christiansen I., Ulrich F. and Olesen J.: Lancet 349, 401–402 (1997).PubMedGoogle Scholar
  41. 41.
    Fozard J.R.: Arch. Int. Pharmacodyn. 329, 111–119 (1995).PubMedGoogle Scholar
  42. 42.
    Jeffrey S.R. and Snyder S.H.: Ann. Rev. Cell Dev Biol. 11, 417–440 (1995).Google Scholar
  43. 43.
    Schmuck K., Ullmer C., Kalkman H.O., Probst A. and Lubbert H.: Eur. J. Neurosci. 8, 959–967 (1996).PubMedGoogle Scholar
  44. 44.
    Humphrey P.P., Feniuk W., Perren M.J., Connor H.E., Oxford A.W., Coates L.H. and Butina D.: Br. J. Pharmacol. 94, 1123–1132 (1988).PubMedGoogle Scholar
  45. 45.
    Humphrey P.P., Feniuk W., Perren M.J., Connor H.E. and Oxford A.W.: Cephalalgia Suppl. 9, 23–33 (1989).Google Scholar
  46. 46.
    Peroutka S.J. and McCarthy B.G.: Eur. J. Pharmacol. 163, 133–136 (1989).PubMedGoogle Scholar
  47. 47.
    Humphrey P.P., Feniuk W. and Perren M.J.: Headache 30, 12–16 (1990).PubMedGoogle Scholar
  48. 48.
    Deliganis A.V. and Peroutka S.J.: Headache 336, 228–231 (1991).Google Scholar
  49. 49.
    Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A. and Hartig P.R.: Proc. Natl. Acad. Sci. USA 89, 3630–3634 (1992).PubMedGoogle Scholar
  50. 50.
    Adham N., Kao H.T., Schecter L.E., Bard J., Olsen M., Urquhart D., Durkin M., Hartig R.R., Weinshank R.L. and Branchek T.A.: Proc. Natl. Acad. Sci. USA 90, 408–412 (1993).PubMedGoogle Scholar
  51. 51.
    Pascual J., Arco C.D., Romon T., Olmo E.D. and Pazos A.: Eur. J. Pharmacol. 295, 271–274 (1996).PubMedGoogle Scholar
  52. 52.
    Bouchelet I., Cohen Z., Case B., Seguela P. and Hamel E.: Mol. Pharmacol. 50, 219–223 (1996).PubMedGoogle Scholar
  53. 53.
    Johnson K.W., Schaus J.M., Durkin M.M., Audia J.E., Kaldor S.W., Flaugh M.E., Adham N., Zgombick J.M., Cohen M.L., Branchek T.A. and Phebus L.A.: NeuroReport 8, 2237–2240 (1997).PubMedGoogle Scholar
  54. 54.
    Cohen M.L., Johnson K.W., Schenck K.W. and Phebus L.A.: Cephalalgia 17, 631–638 (1997).PubMedGoogle Scholar
  55. 55.
    Willett F., Curven N., Adams J. and Armitage M.: Br. Med. J. 304, 1415 (1992).Google Scholar
  56. 56.
    Hillis W.S. and Maclntyre P.D.: Lancet 341, 1564–1565 (1993).PubMedGoogle Scholar
  57. 57.
    Ottervanger J.P., Paalman H.J., Boxma G.L. and Stricker B.H.: Lancet 341, 861–862 (1993).PubMedGoogle Scholar
  58. 58.
    Kalkman H.O.: Life Sci 54, 641–644 (1994).PubMedGoogle Scholar
  59. 59.
    Johnson K.W., Nelson D.L., Wainscott D.B., Lucaites V.L. and Phebus L.A.: Cephalalgia 17, 342 (1997).Google Scholar
  60. 60.
    Meyer J.S., Hata T. and Miai A., in: J.N. Blau (ed.): Migraine-therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 265–302.Google Scholar
  61. 61.
    Heyck H.: Res. Clin. Stud. Headache 22, 1–28 (1969).Google Scholar
  62. 62.
    Saxena P.R. and Verdouw P.D.: J. Physiol. (Lond.) 332, 501–520 (1982).Google Scholar
  63. 63.
    Saxena P.R., DeVries P., Heiligers J.P.C., VanDenBrink A.M., Bax W.A., Barv T. and Wikstrom H.: Eur. J. Pharmacol. 312, 53–62 (1996).PubMedGoogle Scholar
  64. 64.
    Saxena R.R., VanDenBrink A.M., Heiligers J.P.C., Scalbert E. and Lemaitre B.G.: Pharmacol. & Toxicol. 79, 199–204 (1996).Google Scholar
  65. 65.
    Saxena P.R., DeBriew P., Wang W., Heiligers J.P.C., VanDenBrink A.M., Bax W.A. and Yocca F.D.: Naunyn Schmiedeberg’s Arch. Pharmacol. 355, 295–302 (1997).Google Scholar
  66. 66.
    Perren M.J., Feniuk W. and Humphrey P.P.A.: Cephalalgia 9S, 41–46 (1989).Google Scholar
  67. 67.
    Buzzi M.G. and Moskowitz M.A.: Br. J. Pharmacol. 99, 202–206 (1990).PubMedGoogle Scholar
  68. 68.
    Connor H.E., Feniuk W. and Beattie D.T.: Cephalalgia 17, 145–152 (1997).PubMedGoogle Scholar
  69. 69.
    Martin G.R., Robertson A.D., MacLennan S.J., Prentice D.J., Barrett V.J., Buckingham J., Honey A.C., Giles H. and Moneada S.: Br. J. Pharmacol. 121, 157–164 (1997).PubMedGoogle Scholar
  70. 70.
    Brewerton T.D., Murphy D.L., Mueller E.A. and Jimmerson D.C.: Clin. Pharmacol. Ther. 43, 605–609 (1988).PubMedGoogle Scholar
  71. 71.
    Fuller R.W., Kurz K.D., Mason N.R. and Cohen M.L.: Eur. J. Pharmacol. 125, 71–77 (1986).PubMedGoogle Scholar
  72. 72.
    Nelson D.L., Wainscott D.B., Lucaites V.L., Calligaro D.O., Zgombick J.M., Audia J.E., Phebus L.A., and Johnson K.W.: Cephalalgia 17, 341–342 (1997).Google Scholar
  73. 73.
    Nozaki K., Boccalini P. and Moskowitz M.A.: Neurosci. 49, 669–680 (1992).Google Scholar
  74. 74.
    Nozaki K., Moskowitz M.A. and Boccalini P.: Br. J. Pharmacol. 106, 409–415 (1992).PubMedGoogle Scholar
  75. 75.
    Kaube H., Keay K.A., Hoskin K.L., Bandler R. and Goadsby P.J.: Brain Res. 629, 95–102 (1993).PubMedGoogle Scholar
  76. 76.
    Shepheard S.L., Williamson D.J., Williams J., Hill R.G. and Hargreaves R.J.: Neuropharmacol. 34, 255–261 (1995).Google Scholar
  77. 77.
    Buzzi M.G., Sajas D.E. and Moskowitz M.A.: Eur. J. Pharmacol. 165, 251–258 (1989).PubMedGoogle Scholar
  78. 78.
    Buzzi M.G., Moskowitz M.A., Peroutka S.J. and Byun B.: Br. J. Pharmacol. 103, 1421–1428 (1991).PubMedGoogle Scholar
  79. 79.
    Curtin T., Brooks A.P. and Roberts J.A.: Br. Med. J. 305, 713–714 (1992).Google Scholar
  80. 80.
    Luman W. and Gray R.S.: Lancet 341, 1091–1092 (1993).PubMedGoogle Scholar
  81. 81.
    Cavazos J.E., Caress J.B., Chilukuri V.R., Devlin T., Gray L. and Hurwitz B.J.: Lancet 343, 1105–1106 (1994).PubMedGoogle Scholar
  82. 82.
    Cady R.K., Wendt J.K., Kirchner J.R., Sargent J.D., Rothrock J.F. and Skaggs H.: JAMA 165, 2831–2835 (1991).Google Scholar
  83. 83.
    Tfelt-Hansen P.: Cephalalgia 13, 238–244 (1993).PubMedGoogle Scholar
  84. 84.
    Dahlof C., in: J. Olese (ed.): Frontiers in Headache Research Vol 6. Headache Treatment Trial Methodology and New Drugs. Lippencott-Raven Publishers, Philadelphia 1997, pp. 243–251.Google Scholar
  85. 85.
    Bates D., Ashford E., Dawson R., Ensink F.B., Gilhus N.E., Olesen J., Pilgrim A.J. and Shevlin P.: Neurol. 44, 1587–1592 (1994).Google Scholar
  86. 86.
    Phebus L.A., Johnson K.W., Zgombick J.M., Gilbert P.J., VanBelle K., Mancusco V., Nelson D.L.G., Calligaro D.O., Kiefer A.D., Branchek T.A. and Flaugh M.E.: Life Sci. 61, 2117–2126 (1997).PubMedGoogle Scholar
  87. 87.
    Yu X.J., Waeber C., Castanon N., Scearce K., Hen R., Macor J.E., Chauveau J. and Moskowitz M.A.: Mol. Pharmacol. 49, 761–765 (1996).PubMedGoogle Scholar
  88. 88.
    Forbes I.T., Kennet G.A., Gadre A., Ham P., Hayward C., Martin J., Thompson R.T., Wood M., Baxter M.D., Glen G.S., Murphy O.E., Steward B.R. and Blackburn T.P.: J. Med. Chem. 36, 1104 (1993).PubMedGoogle Scholar
  89. 89.
    Forbes I.T., Ham P., Booth D.H., Martin R.T., Thompson M., Baxter G.S., Blackburn T.P., Glen A., Kennett G.A. and Wood M.D.: J. Med. Chem. 38, 2524–2530 (1995).PubMedGoogle Scholar
  90. 90.
    Forbes I.T., Jones G.E., Murphy O.E., Holland V. and Baxter G.S.: J. Med. Chem. 38(6), 855–857 (1995).PubMedGoogle Scholar
  91. 91.
    Bonhaus D.W., Bach C., DeSouza A., Salazar F.H.R., Matsuoka B.D., Zuppan P., Chan H.W. and Eglen R.M.: Br. J. Pharmacol. 115, 622–628 (1995).PubMedGoogle Scholar
  92. 92.
    Thomas D.R., Baxter G.S., Carey J.E., Gager T.L., Gale D.G., Holland V., Muir A., Wilson S. and Wood M.D.: Br. J. Pharmacol. 117, 137P (1996).Google Scholar
  93. 93.
    Nozulak J., Kalkman H.O., Floersheim P., Hoyer D., Schoeffler P. and Buerki H.R.: J. Med. Chem. 38, 28–33 (1995).PubMedGoogle Scholar
  94. 94.
    Cohen M.L., Audia J. and Nelson D.: ID Research Alert-Serotonin 2, 1–5 (1997).Google Scholar
  95. 95.
    Cohen M.L., Schenck K.W., Mabry T.E., Nelson D.L. and Audia J.E.: J. Serotonin Res. 3, 131–144 (1996).Google Scholar
  96. 96.
    Leysen J.E., Gommeren W., Heylen L., Luyten W.H.M.L., Van De Weyer I., Vanhoenacker P., Haegeman G., Schotte A., Van Gompel P., Wouters R. and Lesage A.S.: Mol. Pharmacol. 50, 1567–1580 (1996).PubMedGoogle Scholar
  97. 97.
    Domenech T., Beleta J. and Palacios J.M.: Naunyn Schmiedebergs Arch. Pharmacol. 356, 328–334 (1997).PubMedGoogle Scholar
  98. 98.
    Wurch T., Cathala C., Palmier C., Valentin J.P., John G.W., Colpaert F.C. and Pauwels P.J.: Neurosci. Res. Comm. 18, 155–162 (1996).Google Scholar
  99. 99.
    Wurch T., Palmier C., Colpaert F.C. and Pauwels P.J.: J. Neurochem. 68, 410–418 (1997).PubMedGoogle Scholar
  100. 100.
    Yocca F.D., Buchanan J., Gylys J.A., Hamel E., Iben L.G., Izzarelli D.G., Mahle C.D., Myers R., Noonan J.W., Parker E.M., Williams A.D., Sarbin N., Saxena P., Smith D.W. and Wiener H.L.: Cephalalgia 15, 174 (1995).Google Scholar
  101. 101.
    Gupta P., Napier C.M., Scatchard J., Shepperson N.B. and Wallis R.: Cephalalgia 17, 413 (1997).Google Scholar
  102. 102.
    Yocca F.D., Gylys J.A., Smith D.W., Ruediger E., Yevich J.P., Mahle C., Wiener H., Marcus R., Smith J., Saxena P. and Moskowitz M.: Cephalalgia 17, 404 (1997).Google Scholar
  103. 103.
    The Subcutaneous Sumatriptan International Study Group (1991): N. Engl. J. Med. 325, 316–321.Google Scholar
  104. 104.
    Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J.N., and Baber N.S.: Eur. Neurol. 31, 291–294 (1991).PubMedGoogle Scholar
  105. 105.
    Cady R.K., Rubino, J., Crummett D. and Littlejohn III T.W.: Arch. Fam. Med. 3(9), 766–772 (1994).PubMedGoogle Scholar
  106. 106.
    Sheftell F.D., Weeks R.E., Rapoport A.M., Siegel S., Baskin S. and Arrowsmith F.: Headache 34, 67–72 (1994).PubMedGoogle Scholar
  107. 107.
    Lloyd K.: Eur. Neurol. 34, 40–43 (1994).PubMedGoogle Scholar
  108. 108.
    Visser W.H.: 5-HT1 receptor agonists in the acute treatment of migraine. Clinical, epidemiological and pharmacological aspects. Eburon-Delft, Delft 1996.Google Scholar
  109. 109.
    Ferrari M.D., James M.H., Bates D., Pilgrim A.J., Ashford E.A., Anderson B. and Nappi G.: Cephalalgia 14, 330–338 (1994).PubMedGoogle Scholar
  110. 110.
    Ferrari M.D., Martin G.R., Earl N.L. and Klein K.B.: Eur. Neurol. 36(Suppl2), 19–23 (1996).PubMedGoogle Scholar
  111. 111.
    Zagami A.S.: Neurology 48(3), S25–S28 (1997).PubMedGoogle Scholar
  112. 112.
    Solomon G.D., Cady R.K., Klapper J.A., Earl N.L., Saper J.R. and Ramadan N.M.: Neurology 49(5), 1219–1225 (1997).PubMedGoogle Scholar
  113. 113.
    Gunasekara N.S. and Wiseman, L.R.: CNS Drugs 8(5), 402–408 (1997).Google Scholar
  114. 114.
    Gijsman H., Kramer M.S., Sargent J., Tuchman M., Matzura-Wolfe D., Polis A., Teall J., Block G. and Ferrari M.D.: Cephalalgia 17(6), 647–651 (1997).PubMedGoogle Scholar
  115. 115.
    Sciberras D.G., Polvina W.J., Gertz B.J., Cheng H., Stepanavage M., Wittreich J., Olah T., Edwards M. and Mant T.: Br. J. Clin. Pharamcol. 43, 49–54 (1997).Google Scholar
  116. 116.
    Visser W.H., Terwindt G.M., Reines S.A., Jiang K., Lines C.R. and Ferrari M.D.: Arch Neurol. 53(11), 1132–1137(1996).PubMedGoogle Scholar
  117. 117.
    Schoen J.: Curr. Opin. Neurol. 10, 237–243 (1997).Google Scholar
  118. 118.
    Jackson N.C. for the Eletriptan Steering Committee: Cephalalgia 16, 368 (1996).Google Scholar
  119. 119.
    Cabarrocas X. and Salva M.: Cephalalgia 17, 421 (1997).Google Scholar
  120. 120.
    Goldstein J., Schellens R., Diener H.C., Dahlof C., Olesen J., Senard J.M., Steiner T.J. and Simard D., in: J. Olesen, P. Tfelt-Hansen (eds.): Headache treatment, trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia 1997, pp. 279–285.Google Scholar
  121. 121.
    Diener H.C., Gendolla A., Juptner M., Kaube H. and Limmroth V: Eur Neurol. 38, 167–174 (1997).PubMedGoogle Scholar
  122. 122.
    Mathew N.T., in: N.T. Mathew (ed.): Advances in Headache. W.B. Saunders Company, Philadelphia 1997, vol. 15(1), 61–83.Google Scholar
  123. 123.
    Winner P., Ricalde O., Le Force B., Saper J., and Margul B.: Arch. Neurol. 53, 180–184 (1996).PubMedGoogle Scholar

Copyright information

© Springer Basel AG 1998

Authors and Affiliations

  • Kirk W. Johnson
    • 1
  • Lee A. Phebus
    • 1
  • Marlene L. Cohen
    • 1
  1. 1.Lilly Research LaboratoriesEli Lilly and Company, Lilly Corporate CenterIndianapolisUSA

Personalised recommendations